HomeCompareALBO vs BTI

ALBO vs BTI: Dividend Comparison 2026

ALBO yields 4.53% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $10.8K in total portfolio value
10 years
ALBO
ALBO
● Live price
4.53%
Share price
$44.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$605.56
Full ALBO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ALBO vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBOBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBO + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBO
Annual income on $10K today (after 15% tax)
$385.05/yr
After 10yr DRIP, annual income (after tax)
$514.73/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $1,853.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBO + BTI for your $10,000?

ALBO: 50%BTI: 50%
100% BTI50/50100% ALBO
Portfolio after 10yr
$32.3K
Annual income
$1,696.10/yr
Blended yield
5.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ALBO
Analyst Ratings
7
Buy
5
Hold
Consensus: Buy
Price Target
$44.00
-0.3% upside vs current
Range: $42.00 — $48.00
Altman Z
0.5
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBO buys
0
BTI buys
0
No recent congressional trades found for ALBO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBOBTI
Forward yield4.53%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$26.9K$37.7K
Annual income after 10y$605.56$2,786.64
Total dividends collected$5.3K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$44.00$40.00

Year-by-year: ALBO vs BTI ($10,000, DRIP)

YearALBO PortfolioALBO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,153$453.00$11,299$598.92$146.00BTI
2$12,406$472.18$12,794$703.91$388.00BTI
3$13,765$490.86$14,518$829.07$753.00BTI
4$15,238$509.01$16,513$978.64$1.3KBTI
5$16,831$526.60$18,827$1,157.84$2.0KBTI
6$18,553$543.61$21,518$1,373.12$3.0KBTI
7$20,411$560.02$24,657$1,632.46$4.2KBTI
8$22,416$575.82$28,329$1,945.74$5.9KBTI
9$24,576$591.00$32,637$2,325.33$8.1KBTI
10$26,902$605.56$37,708$2,786.64$10.8KBTI

ALBO vs BTI: Complete Analysis 2026

ALBOStock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Full ALBO Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ALBO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBO vs SCHDALBO vs JEPIALBO vs OALBO vs KOALBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.